RxDoctor Payments Data

David Hardin, MD

Internal Medicine · Birmingham, ALNPI 1629489059

Payments from drug & device makers

$2,296in general payments, 2019–2025

Across 147 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$877
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$366
  • Braeburn Inc.$287
  • Indivior Inc.$269
  • Collegium Pharmaceutical, Inc.$121
  • IBSA Pharma Inc.$55
  • plus $322 from 13 others

What the payments were for

  • Food & beverage$2,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,296 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$116,307
Medicare patients
175
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl747$170,113
RelistorMethylnaltrexone Bromide52$120,297
Xtampza ErOxycodone Myristate103$68,474
ZubsolvBuprenorphine Hcl/Naloxone Hcl90$66,496
SuboxoneBuprenorphine Hcl/Naloxone Hcl64$46,271
BelbucaBuprenorphine Hcl46$40,512
Orphenadrine-Aspirin-CaffeineOrphenadrine/Aspirin/Caffeine26$35,369
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,368$30,655
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,018$24,731
NucyntaTapentadol Hcl17$20,686
Buprenorphine75$19,111
OzempicSemaglutide20$18,702
GraliseGabapentin17$15,397
LinzessLinaclotide21$14,162
OxycontinOxycodone Hcl23$13,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl$13$202,6891,013 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$121$129,672166 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$366$120,29752 claims
Orexo US, Inc.Zubsolv$28$66,49690 claims
Indivior Inc.Suboxone$269$46,27164 claims
Novo NordiskOzempic$19$18,70220 claims
Redhill Biopharma Inc.Movantik$11$13,81427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →